Leukemia News

Approximately 14% of adults with acute myeloid leukemia harbored germline pathogenic or likely pathogenic variants in a hematologic malignancy predisposition gene, according to study results published in Blood.

CHICAGO – Healio gathered the best, brightest and boldest group of oncologists during the ASCO Annual Meeting in Chicago to celebrate our inaugural Healio Disruptive Innovators.

A phase 2/phase 3 study assessed intramuscular asparaginase Erwinia chrysanthemi (recombinant)-rywn for patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who developed hypersensitivity to E. coli-derived L-asparaginase.

One of the major challenges in the field of nanomedicine is translating in vitro performance of nanoparticles to in vivo studies, a factor that may hinder the development of nanoparticles as drug delivery vehicles.

Nanomedicine has been a promising area of clinical research — particularly in the cancer setting — for decades, and experts said its potential has only increased with advances in cancer diagnostics and therapeutics.

CHICAGO — Asciminib continued to confer superior efficacy and better safety and tolerability than bosutinib among patients with chronic-phase chronic myeloid leukemia, according to study results presented during ASCO Annual Meeting.

In its 2022 Cancer Disparities Progress Report, American Association for Cancer Research discussed advances made in closing substantial gaps in care while underscoring the need for further progress.

CHICAGO — The addition of daratumumab to chemotherapy improved outcomes among younger patients with relapsed or refractory T-cell acute lymphoblastic leukemia, study results showed.

CHICAGO — During the ASCO Annual Meeting, Healio honored our inaugural Healio Disruptive Innovators in hematology/oncology.

Women demonstrated a 34% increased risk for severe adverse events from any cancer treatment compared with men, according to a study published in Journal of Clinical Oncology.